Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 108. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Use of artificial intelligence to enhance detection of nodal metastases834
SABR for operable stage I non-small-cell lung cancer: comparison to surgery585
Patients with cancer in Louisiana denied fertility preservation cover524
Combination immunotherapy in chemotherapy in gastric cancer498
US FDA proposes stronger laboratory test oversight460
Correction to Lancet Oncol 2022; 23: 1124–26442
COVID-19 pandemic causes cervical cancer screening crisis412
Enhancing equity and long-term impact assessments in radiotherapy environmental studies387
Medical treatment for active breast cancer brain metastases387
IVLBCL mimicking VEXAS syndrome381
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer367
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy345
The GLOW trial in chronic lymphocytic leukaemia330
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer319
Dual therapy in metastatic castration-resistant prostate cancer315
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply310
Olanzapine for chemotherapy-induced nausea and vomiting control301
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer301
Study bolsters concerns about US FDA accelerated drug approvals301
CAR T cells for the long run in aggressive B-cell lymphoma299
Correction to Lancet Oncol 2021; 22: 1081–92296
Antibody–drug conjugates in acute myeloid leukaemia: more research needed282
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC279
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial271
The future of precise cancer chronotherapeutics271
The silent malignant mesothelioma epidemic: a call to action259
Navigating the complexity: reflections on the development of perioperative cancer treatments254
Health insurance system in Japan faces risk of politicisation241
A new generation of comprehensive precision oncology trials240
Survivorship after neoadjuvant chemotherapy239
Italy to pass law on the right to be forgotten for cancer survivors233
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply233
SANO trial: innovations, risks, and unanswered questions230
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t227
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation221
Concern for cancer drugs in USA–EU tariff war219
Palliative radiotherapy for hepatic cancer pain215
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis206
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial205
US Surgeon General calls for cancer warning labels on alcohol205
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges203
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries201
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, 190
Precision medicine for children with cancer189
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi189
Innovation in gynaecological cancer: highlighting global disparities187
Determining the optimal use of approved drugs in oncology184
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply180
New national cancer registry for France180
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study180
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX180
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus180
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies177
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study176
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult174
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm174
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial173
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia172
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial169
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial168
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under164
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 163
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 163
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery161
Focus where it matters: turning insights into advocacy159
Decentralised, point-of-care CAR-T for multiple myeloma157
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study155
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer154
A biobank perspective on use of tissue samples donated by trial participants154
Common Sense Oncology: including everyone152
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?149
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply146
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply145
Essential anticancer medicines for children: defining what matters most for Europe144
Importance of clinical research for the UK's 10-year cancer plan143
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:142
Radiotherapy with genomic-adjusted radiation dose141
Mantle cell lymphoma: is it time for risk-adapted treatment?140
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire139
Radiotherapy with genomic-adjusted radiation dose139
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer135
Lung cancer rates highest among British Bangladeshi men134
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus134
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis134
Antimicrobial resistance in patients with haematological malignancies: a scoping review132
WHO reports health service disruptions due to suspensions of aid131
Balancing clinical benefit and social value: challenges in HTA assessments130
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer130
Cancer on the agenda during IAEA Director General's visit to Chile128
Daratumumab maintenance in patients with myeloma127
Challenges and prospects for cancer treatment in prison settings126
Correction to Lancet Oncol 2023; 24: e242124
2022 ASTRO annual meeting122
Correction to Lancet Oncol 2020; 21: 699–709122
Clearing the radiotherapy backlog: innovation to pave the way121
A growing vulvar mass in a post-menopausal woman118
Lebanon faces critical shortage of drugs118
Shortages of essential medications for children with cancer in Colombia117
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA116
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations115
Alcohol and the global burden of cancer: what are we missing?113
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer113
The challenges of cancer care for the LGBTQ+ community111
India rolls out HPV vaccination111
Syrian cancer patients regain treatment access in Türkiye111
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial110
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study108
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update108
0.086071014404297